In this interview, Physitrack’s CEO Henrik Molin talks about the Q3 2026 report. Revenue grew 14%, the strongest growth this year, and the core Physitrack platform grew 26%. Henrik explains what is behind the growth, when he expects margins to return to the 40–45% target, and what the two US healthcare system wins mean. He also discusses which of the three new products has the most potential, early uptake for the EMR, and whether there is room for more price increases.
LÄS MER
